1. Introduction {#s0005}
===============

Chronic obstructive pulmonary disease (COPD), as a significant major cause of chronic morbidity and mortality worldwide, is characterized by incompletely reversible airflow limitation and persistent airway inflammation ([@bb0055]). Previous studies have demonstrated that chronic inflammation and varying degrees of emphysematous alveolar destruction are the key pathological features of the disease ([@bb0185]). Some studies have revealed that an imbalance of endogenous proteinases and antiproteinases, inflammatory cells, proinflammatory mediators, and oxidative stress were responsible for the pathogenesis of COPD ([@bb0200]). Genetic factors and environmental exposures like tobacco smoke are also involved in the pathogenesis of COPD ([@bb0165]). Tobacco smoke is regarded the most important risk factor for COPD, and smokers account for 80--90% of all COPD patients ([@bb0220]).

However, only 10--15% of smokers develop clinically significant COPD ([@bb0135; @bb0175]). Many COPD patients have a family history and several studies have showed that the individual\'s risk differences to tobacco smoke injury may be related to genetic factors and the genetic factors may also play an important role in the pathogenesis of COPD ([@bb0080; @bb0145]). Therefore, it is widely believed that COPD results from an interaction between genetic factors and environmental exposures. A lot of candidate gene studies have been carried out to identify genetic susceptibility factors for COPD over the past few years ([@bb0210; @bb0225; @bb0015; @bb0030; @bb0150]).

Previous studies have demonstrated that the development of COPD may be associated with the genetic variation in the enzymes that detoxify cigarette smoke products, such as *glutathione S-transferases* (*GSTs*)*. GSTs*, a functionally diverse family of enzymes, were involved in the conjugation of a wide range of electrophilic substances with glutathione, facilitating detoxification, metabolism and excretion of the smoke products. Of the six classes of *GSTs*, i.e*. alpha* (*GSTA*), *mu* (*GSTM1*), *pi* (*GSTP1*), *theta* (*GSTT1*), *sigma and kappa*, *GSTP1* was expressed more abundantly in respiratory tissue ([@bb0010]). A number of studies have focused on the relationship between *GSTP1 105Val*/*Val* genotype and COPD risk in different ethnic populations with conflicting results, probably due to small sample sizes in those studies. Meta-analysis is a good statistical method to combine the results from multiple studies in an effort to increase power, improve estimates of the size of the effect and/or to resolve uncertainty when reports disagree. Yan et al. performed a meta-analysis included ten studies with a total of 1140 cases and 1263 controls and suggested a significant association between *GSTP1* gene polymorphism and COPD risk ([@bb0245]). Based on the most updated information and the current available evidence, we performed this updated meta-analysis to drive a more precise estimation of *GSTP1 Ile* (*105*) *Val* gene polymorphism and COPD risk.

2. Materials and methods {#s0010}
========================

2.1. Search strategy {#s0015}
--------------------

This meta-analysis was performed according to the standard MOOSE guideline ([@bb0190]).PubMed, EMBASE, Cochrane library, Web of science and China Knowledge Resource Integrated Database (until May 1, 2015) were searched using search terms as "(*polymorphism OR variants OR mutation*) *AND COPD AND* (*GST OR Glutathione-S-transferase OR GSTP1*)". Studies published in English or in Chinese language were selected. Case--control studies containing available genotype frequencies of *GSTP1 Ile* (*105*) *Val* were chosen. Related reference articles were also searched to identify other relevant publications. Unpublished data were not included.

2.2. Inclusion and exclusion criteria {#s0020}
-------------------------------------

Eligible studies were selected following inclusion criteria: 1) *GSTP1 Ile* (*105*) *Val* polymorphism and COPD risk; 2) human case--control design; 3) application of standardized clinical or pathologic criteria for the diagnosis of COPD; 4) studies that reported the frequency of the *GSTP1 Ile* (*105*) *Val gene* polymorphism as number of cases and controls according to the three variant genotypes of either polymorphisms; and 5) published in English or Chinese. The criteria for the exclusion of studies are as follows: 1) not related to the *GSTP1 Ile* (*105*) *Val* gene polymorphism and COPD risk; 2) not a primary case--control study; 3) no usable or sufficient genotype data reported; 4) studies whose allele frequency in the control population deviated from the Hardy--Weinberg Equilibrium (HWE) at a p value equal or less than 0.01; 5) case reports, letter to Editor, book chapters or reviews. The study inclusion and exclusion procedures are summarized in [Fig. 1](#f0005){ref-type="fig"}.

2.3. Data extraction {#s0025}
--------------------

The data from all qualified studies were extracted by two investigators independently according to the selection standard listed above. Discrepancies were solved through discussion until agreement was reached. The following information was extracted: the first author\'s name, year of publication, Ethnicity, the source of control group evidence of Hardy-Weinberg equilibrium (HWE) in controls, the sample size, number of cases and controls with the three genotypes.

2.4. Statistical analysis {#s0030}
-------------------------

STATA software (Version 13.0) was used for all statistical analyses. Two-sided *P* values less than 0.05 were considered statistically significant. The strength of the association between the *GSTP1 Ile* (*105*) *Val* gene polymorphism and COPD risk was assessed by the odds ratios (ORs) with 95% CIs. The pooled ORs were calculated for the homozygote model (*105Val*/*Val* vs*.105Ile*/*Ile*), heterozygote model (*105Ile*/*Val* vs*.105Ile*/*Ile*), dominant model (*105Val*/*Val* ~+~* 105Ile*/*Val* vs*. 105Ile*/*Ile*), recessive model (*105Val*/*Val* vs*. 105Ile*/*Val* +* 105Ile*/*Ile*), and an additive model (*Val* vs*. Ile*) ([@bb0255; @bb0250]). For the control groups for each study, the observed genotype frequencies of the *GSTP1 Ile* (*105*) *Val* polymorphism were evaluated for Hardy--Weinberg equilibrium ([@bb0215; @bb0130; @bb0195]). Cochran\'s Q-statistic and the I^2^ metric were conducted to assess heterogeneity between studies, P \< 0.10 and I^2^ \> 50% were considered to indicate the existence of significant heterogeneity ([@bb0070; @bb0110]). If the heterogeneity test result returned P \> 0.1, the pooled ORs were analyzed using the random-effects model ([@bb0035]), or else, the fixed effects model was used ([@bb0140]). Sensitivity analyses were also performed after sequential removal of each study ([@bb0045]). We also tried to assess the source of heterogeneity by region, publication year, control source, and sample size ([@bb0065; @bb0240]). Lastly, Begg\'s funnel plot and Egger\'s test were used to examine statistically any publication bias ([@bb0160]).

3. Results {#s0035}
==========

3.1. Characteristics of the included studies {#s0040}
--------------------------------------------

In accordance with the inclusion criteria, seventeen case--control studies with 1892 cases and 2012 controls were included based on the search criteria for risk of COPD related to the *GSTP1* polymorphism ([@bb0060; @bb0260; @bb0125; @bb0105; @bb0235; @bb0265; @bb0025; @bb0050; @bb0170; @bb0085; @bb0005; @bb0040; @bb0020; @bb0205; @bb0120; @bb0270; @bb0230]). All of the 17 studies were published between 1997 and 2014. No overlap occurred between the studies based on case or control participation. The characteristics of all included studies are summarized in [Table 1](#t0005){ref-type="table"}.

3.2. Results of the overall meta-analysis {#s0045}
-----------------------------------------

The main results of meta-analysis on the association between the *GSTP1 Ile* (*105*) *Val* polymorphism and COPD risk are listed in [Table 2](#t0010){ref-type="table"}. The *GSTP1 Ile* (*105*) *Val* polymorphism showed pooled odds ratios for the homozygote comparison ([Fig. 2](#f0010){ref-type="fig"}, OR = 1.501, 95%CI \[0.862, 2.614\]), heterozygote comparison ([Fig. 3](#f0015){ref-type="fig"}, OR = 0.924, 95%CI \[0.733, 1.165\]), dominant model (OR = 1.003, 95%CI \[0.756, 1.331\]), recessive model (OR = 1.510, 95%CI \[0.934, 2.439\]), and an additive model (OR = 1.072, 95%CI \[0.822, 1.398\]).

3.3. Sub-group analysis {#s0050}
-----------------------

We performed a sub-group analysis stratified by ethnicity. There were 11 studies based on Asian population and 6 studies based on Caucasian population. The pooled OR was 1.586, 95%CI \[0.814, 3.088\] for Asian population, 1.476, 95%CI \[0.558, 3.906\] for Caucasian population in homozygote comparison. The subgroup analysis results for the all genetic models are listed in detail in [Table 3](#t0015){ref-type="table"}.

3.4. Heterogeneity test {#s0055}
-----------------------

There was a significant heterogeneity, in homozygote comparison: chi-squared = 52.95 (d.f. = 16) p = 0.000, I-squared = 69.8%, and in Heterozygote comparison: chi-squared = 36.65 (d.f. = 16) p = 0.002, I-squared = 56.3%. We assessed the source of heterogeneity by region, publication year, control source, and sample size. However, we did not observe any sources that contributed to the substantial heterogeneity. The meta-regression analysis did not yield any significant difference between subgroup analysis.

3.5. Sensitivity analysis {#s0060}
-------------------------

We conducted sensitivity analyses to ascertain the primary origin of the heterogeneity. Through sensitivity analysis, the current meta-analysis showed that no individual study had marked effect on the pooled ORs ([Fig. 4](#f0020){ref-type="fig"}).

3.6. Publication bias {#s0065}
---------------------

Funnel plot was generated to assess publication bias. Begg\'s test and Egger\'s test were performed to evaluate funnel plot symmetry statistically. The results showed no publication bias: Begg\'s test Pr \> \| z \| = 0.343 and Egger\'s test P \> \| t \| = 0.263 ([Fig. 5](#f0025){ref-type="fig"}).

4. Discussion {#s0070}
=============

COPD, one of the major health challenges, is the fourth leading cause of death globally presently, and it is predicted to become the third leading cause by 2030 ([@bb0090]). It is likely to be a complex interplay between genetic and environmental factors. A series of different genes were considered to play important roles in the metabolism of toxic substances in cigarette smoke, airway hyperresponsiveness, and the inflammatory response to cigarette smoke ([@bb0180]).GSTs are derived from a superfamily of genes; they catalyze the conjugation of reactive chemical intermediates to soluble glutathione and may play a role in cellular defense by detoxifying various toxic substrates in cigarette smoke ([@bb0115]).Many previous studies have explored the association between *GSTP1 105Val*/*Val* genotype and COPD risk in different ethnic populations with conflicting results. As so far, only one meta-analyses, which was nested in case--control studies, have investigated the association of *GSTP1 Ile* (*105*) *Val* polymorphism and COPD susceptibility. Yan et al. performed a meta-analysis included ten studies with a total of 1140 cases and 1263 controls and suggested a significant association between *GSTP1 Ile* (*105*) *Val* gene polymorphism and COPD risk ([@bb0245]).Considering a series of new articles have been published we performed this updated meta-analysis to drive a more precise estimation of *GSTP1 Ile* (*105*) *Val* gene polymorphism and COPD risk.

According to the inclusion criteria 17 studies with 1892 cases and 2012 controls were included the current meta-analysis. To the best of our knowledge, the current meta-analysis is the largest one to investigate the association between *GSTP1 Ile* (*105*) *Val* gene polymorphism and COPD risk. The results showed no significant association between *GSTP1 Ile* (*105*) *Val* gene polymorphism and COPD risk in any genetic models. The results of subgroup analysis also showed no significant association between *GSTP1 Ile* (*105*) *Val gene* polymorphism and COPD risk in Asian population and Caucasian population. There was a significant heterogeneity, and we conducted sensitivity analyses to ascertain the primary origin of the heterogeneity. Through sensitivity analysis, the current meta-analysis showed that no individual study had significant effect on the pooled ORs. Funnel plot was generated to assess publication bias. Begg\'s test and Egger\'s test were performed to evaluate funnel plot symmetry statistically. No publication bias was detected in our meta-analysis.

Of course, we should be aware of that the hypothesis considering no association between *GSTP1 Ile* (*105*) *Val* gene polymorphism and COPD risk merely on the basis of the negative results in this study. If a putative genetic association is of small magnitude with point estimates less than 1.5, the small and underpowered studies may be unable to identify true genetic associations ([@bb0095; @bb0100; @bb0075]). Thus, more evidence is needed to support or deny such an association. By means of meta-analysis, a statistical technique for combining the results from independent studies, we drew a more reliable conclusion on the influence of *GSTP1 Ile* (*105*) *Val* gene polymorphism on COPD risk. However, COPD might be a result of multi-factors, future research should investigate not only individual genes, but also gene--gene interactions, other SNPs such as *GSTM1*, *GSTT1.*

Several potential limitations of this meta-analysis should be discussed: 1) although the funnel plot and Begg\'s Test showed no publication bias, selection bias may have occurred because only studies in English or Chinese were selected; 2) there was a significant heterogeneity. We assessed the source of heterogeneity by region, publication year, control source, and sample size. However, we did not observe any sources that contributed to the substantial heterogeneity. The meta-regression analysis did not yield any significant difference between subgroup analysis. Through sensitivity analysis, the current meta-analysis showed that no individual study had marked effect on the pooled ORs. However, this study also has some clear advantages: 1) this is the meta-analysis on the most updated information; 2) we performed a sub-group analysis stratified by ethnicity; 3) sensitivity analysis showed no individual study had marked effect on the overall results; 4) the scientific search and selection method significantly increased the reality of this meta-analysis; 5) no publication bias was detected.

In conclusion, the current meta-analysis, based on the most updated information, showed no significant association between *GSTP1 Ile* (*105*) *Val* gene polymorphism and COPD risk in any genetic models. The results of subgroup analysis also showed no significant association between *GSTP1 Ile* (*105*) *Val* gene polymorphism and COPD risk in Asian population and Caucasian population. Further studies involving large populations and careful control with age, sex, ethnicity, and cigarette smoking are greatly needed.
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###### 

Characteristics of studies included in this meta-analysis.

  Author             Year   Ethnicity   Source of controls   Adjustment for smoking               Case                    Control        HWE(P)
  ------------------ ------ ----------- -------------------- ------------------------ ----- ----- ------ ---- ----- ----- --------- ---- --------
  Harries et al.     1997   Caucasian   Healthy controls     No                       79    34    35     10   155   79    66        10   0.4396
  Ishii et al.       1999   Asian       Healthy controls     Yes                      53    42    11     0    50    26    22        2    0.3104
  Lu et al.          2002   Asian       Healthy controls     Yes                      97    70    22     5    67    41    24        2    0.4940
  Yim et al.         2002   Asian       Checkup              No                       89    63    24     2    94    57    35        2    0.1995
  Zhang et al.       2003   Asian       Healthy controls     Yes                      57    47    5      5    48    44    3         1    0.0110
  Cheng et al.       2004   Asian       Checkup              Yes                      184   97    78     9    212   99    98        15   0.1591
  Gaspa et al.       2004   Caucasian   Checkup              No                       75    35    35     5    90    47    36        7    0.9767
  Xiao et al.        2004   Asian       Healthy controls     Yes                      100   70    29     1    100   57    40        3    0.1959
  Hu et al.          2005   Asian       Healthy controls     Yes                      50    45    3      2    68    59    5         4    0.0000
  Rodriguez et al.   2005   Caucasian   Checkup              No                       98    52    36     10   198   97    88        13   0.2372
  Calikoglu et al.   2006   Caucasian   Healthy controls     Yes                      144   88    42     14   150   57    57        36   0.0059
  Fang et al.        2006   Asian       Healthy controls     No                       87    65    18     4    91    74    16        1    0.8972
  Vibhuti et al.     2007   Asian       Healthy controls     Yes                      202   105   75     22   136   90    42        4    0.7336
  Yeung et al.       2007   Asian       Healthy controls     Yes                      163   112   43     8    161   112   47        2    0.2280
  Lakhdar et al.     2010   Caucasian   Healthy controls     Yes                      234   81    104    49   182   84    79        19   0.9468
  Wu et al.          2014   Asian       Healthy controls     Yes                      150   113   18     19   150   132   11        7    0.0000
  Zuntar et al.      2014   Caucasian   Healthy controls     No                       30    10    16     4    60    34    25        1    0.1314

###### 

Results of the overall meta-analysis.

  Contrast       OR,95% CI                 Heterogeneity                                                  Z and P
  -------------- ------------------------- -------------------------------------------------------------- ---------------------
  Homozygote     1.501, \[0.862, 2.614\]   Chi-squared = 52.95 (d.f. = 16) p = 0.000, I-squared = 69.8%   z = 1.44, p = 0.151
  Heterozygote   0.924, \[0.733, 1.165\]   Chi-squared = 36.65 (d.f. = 16) p = 0.002, I-squared = 56.3%   z = 0.67, p = 0.503
  Dominant       1.003, \[0.756, 1.331\]   Chi-squared = 62.67 (d.f. = 16) p = 0.000, I-squared = 74.5%   z = 0.02, p = 0.984
  Recessive      1.510, \[0.934, 2.439\]   Chi-squared = 41.41 (d.f. = 16) p = 0.000, I-squared = 61.4%   z = 1.68, p = 0.093
  Additive       1.072, \[0.822, 1.398\]   Chi-squared = 85.96 (d.f. = 16) p = 0.000, I-squared = 81.4%   z = 0.51, p = 0.610

###### 

Results of sub-group analysis.

  Ethnicity   Comparisons   Homozygote                Heterozygote              Dominant                  Recessive                 Additive
  ----------- ------------- ------------------------- ------------------------- ------------------------- ------------------------- -------------------------
  Caucasian   6             1.476, \[0.558, 3.906\]   1.040, \[0.697, 1.552\]   1.110, \[0.664, 1.854\]   1.393, \[0.622, 3.118\]   1.131, \[0.708, 1.806\]
  Asian       11            1.586, \[0.814, 3.088\]   0.858, \[0.638, 1.154\]   0.948, \[0.664, 1.353\]   1.663, \[0.914, 3.025\]   1.038, \[0.738, 1.460\]
  Overall     17            1.501, \[0.862,2.614\]    0.924, \[0.733, 1.165\]   1.003, \[0.756, 1.331\]   1.510, \[0.934, 2.439\]   1.072, \[0.822, 1.398\]
